Piper Sandler lowered the firm’s price target on Health Catalyst (HCAT) to $8 from $12 and keeps an Overweight rating on the shares following quarterly results. Despite the top-line drama, the firm thinks Health Catalyst can deliver $39.0M of adjusted EBITDA in 2025.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HCAT:
- Health Catalyst price target lowered to $10 from $11 at Canaccord
- Health Catalyst price target lowered to $7 from $9 at RBC Capital
- Health Catalyst to Acquire Upfront Healthcare Services
- Health Catalyst to acquire Upfront Healthcare Services, terms not disclosed
- Health Catalyst price target lowered to $10 from $10.50 at Citi